Michael Schmitt

11.9k total citations · 1 hit paper
273 papers, 7.1k citations indexed

About

Michael Schmitt is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Michael Schmitt has authored 273 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 130 papers in Oncology, 118 papers in Immunology and 82 papers in Molecular Biology. Recurrent topics in Michael Schmitt's work include CAR-T cell therapy research (99 papers), Immunotherapy and Immune Responses (73 papers) and Immune Cell Function and Interaction (46 papers). Michael Schmitt is often cited by papers focused on CAR-T cell therapy research (99 papers), Immunotherapy and Immune Responses (73 papers) and Immune Cell Function and Interaction (46 papers). Michael Schmitt collaborates with scholars based in Germany, United States and China. Michael Schmitt's co-authors include Anita Schmitt, Jochen Greiner, Lawrence A. Loeb, Hartmut Döhner, Carsten Müller‐Tidow, Maria‐Luisa Schubert, Peter Dreger, Jesse J. Salk, Mark Ringhoffer and Krzysztof Giannopoulos and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Angewandte Chemie International Edition.

In The Last Decade

Michael Schmitt

265 papers receiving 7.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Side-effect management of chimeric antigen receptor (CAR) T-cell therapy

2020 340 citations Maria‐Luisa Schubert, Michael Schmitt et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Schmitt Germany	43	3.2k	2.6k	2.6k	1.3k	845	273	7.1k
David Buck United Kingdom	37	2.5k 0.8×	3.0k 1.2×	3.7k 1.4×	788 0.6×	637 0.8×	66	9.1k
Arinobu Tojo Japan	45	1.9k 0.6×	1.6k 0.6×	3.1k 1.2×	2.5k 1.9×	515 0.6×	364	8.2k
Robert Sackstein United States	48	1.8k 0.6×	2.7k 1.0×	2.4k 0.9×	2.2k 1.7×	645 0.8×	150	7.5k
Kenneth I. Weinberg United States	51	2.2k 0.7×	4.1k 1.6×	3.9k 1.5×	2.1k 1.7×	1.7k 2.0×	180	10.8k
Stephen D. Gillies United States	50	3.7k 1.2×	4.5k 1.7×	4.0k 1.6×	524 0.4×	1.4k 1.6×	153	9.8k
Edus H. Warren United States	43	2.3k 0.7×	3.7k 1.4×	1.3k 0.5×	2.9k 2.3×	746 0.9×	149	7.0k
Kenji Kawabata Japan	42	2.1k 0.7×	1.7k 0.6×	3.6k 1.4×	512 0.4×	1.6k 1.8×	182	7.4k
Yong‐Guang Yang China	50	1.4k 0.4×	3.8k 1.5×	3.2k 1.3×	1.6k 1.2×	1.7k 2.0×	244	9.7k
Boris Fehse Germany	54	2.7k 0.8×	1.5k 0.6×	5.1k 2.0×	2.0k 1.6×	2.8k 3.3×	252	9.2k
Dean A. Lee United States	51	5.7k 1.8×	5.2k 2.0×	2.3k 0.9×	872 0.7×	1.4k 1.6×	248	8.7k

Countries citing papers authored by Michael Schmitt

Since Specialization

Citations

This map shows the geographic impact of Michael Schmitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Schmitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Schmitt more than expected).

Fields of papers citing papers by Michael Schmitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Schmitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Schmitt. The network helps show where Michael Schmitt may publish in the future.

Co-authorship network of co-authors of Michael Schmitt

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Schmitt. A scholar is included among the top collaborators of Michael Schmitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Schmitt. Michael Schmitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Qian, et al.. (2024). Structurally Optimized, IL-2-Armored CLL1 CAR-NK Cells Are Highly Potent Effectors Against AML without Hpsc Toxicity. Blood. 144(Supplement 1). 3440–3440. 3 indexed citations

Claus, Maren, Carsten Watzl, Philipp Kolb, et al.. (2024). Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study. Arthritis Research & Therapy. 26(1). 211–211. 7 indexed citations

Roider, Tobias, Norman Mack, Peter‐Martin Bruch, et al.. (2024). CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models. Blood. 144(7). 784–789. 7 indexed citations

Chichagova, Valeria, Μαρία Γεωργίου, Birthe Dorgau, et al.. (2023). Incorporating microglia‐like cells in human induced pluripotent stem cell‐derived retinal organoids. Journal of Cellular and Molecular Medicine. 27(3). 435–445. 21 indexed citations

John, Lukas, Sandra Sauer, Ute Hegenbart, et al.. (2023). Idecabtagene Vicleucel Is Well Tolerated and Effective in Relapsed/Refractory Myeloma Patients with Prior Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 29(10). 609.e1–609.e6. 4 indexed citations

Gong, Wenjie, Lei Wang, Maria‐Luisa Schubert, et al.. (2022). HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma. Biomedicines. 10(2). 373–373. 4 indexed citations

Sauer, Tim, Kathan Parikh, Sandhya Sharma, et al.. (2021). CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity. Blood. 138(4). 318–330. 142 indexed citations

Goldman, Jason D., Hong Zhao, Alec Pankow, et al.. (2021). Intra-host changes in Kaposi sarcoma-associated herpesvirus genomes in Ugandan adults with Kaposi sarcoma. PLoS Pathogens. 17(1). e1008594–e1008594. 14 indexed citations

Gong, Wenjie, Lei Wang, Sophia Stock, et al.. (2021). Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells. Cells. 10(1). 152–152. 4 indexed citations

10.

Ni, Ming, Lei Wang, Wenjie Gong, et al.. (2021). Response to extracorporeal photopheresis therapy of patients with steroid-refractory/-resistant GvHD is associated with up-regulation of Th22 cells and Tfh cells. Cytotherapy. 24(3). 311–319. 9 indexed citations

11.

Schubert, Maria‐Luisa, Alexander Kunz, Anita Schmitt, et al.. (2020). Assessment of CAR T Cell Frequencies in Axicabtagene Ciloleucel and Tisagenlecleucel Patients Using Duplex Quantitative PCR. Cancers. 12(10). 2820–2820. 14 indexed citations

12.

Yoo, Keun-Young, Sophia Stock, Lei Wang, et al.. (2020). Ibrutinib for improved chimeric antigen receptor T‐cell production for chronic lymphocytic leukemia patients. International Journal of Cancer. 148(2). 419–428. 52 indexed citations

13.

Sellner, Leopold, Nicola Giesen, Maria‐Luisa Schubert, et al.. (2020). B‐cell maturation antigen‐specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives. International Journal of Cancer. 147(8). 2029–2041. 9 indexed citations

14.

Yoo, Keun-Young, Yibin Liu, Lei Wang, et al.. (2019). Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies. International Journal of Molecular Sciences. 20(10). 2469–2469. 15 indexed citations

15.

Stock, Sophia, Michael Schmitt, & Leopold Sellner. (2019). Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy. International Journal of Molecular Sciences. 20(24). 6223–6223. 106 indexed citations

16.

Gdynia, Georg, Tadeusz Robak, Jürgen Kopitz, et al.. (2018). Distinct Activities of Glycolytic Enzymes Identify Chronic Lymphocytic Leukemia Patients with a more Aggressive Course and Resistance to Chemo-Immunotherapy. EBioMedicine. 32. 125–133. 4 indexed citations

17.

Hofmann, Susanne, Michael Schmitt, Marlies Götz, et al.. (2018). Donor lymphocyte infusion leads to diversity of specific T cell responses and reduces regulatory T cell frequency in clinical responders. International Journal of Cancer. 144(5). 1135–1146. 10 indexed citations

18.

Schmitt, Michael, Patrick Wuchter, Eike C. Buss, et al.. (2014). Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma. Transfusion. 55(2). 275–283. 33 indexed citations

19.

Bullinger, Lars, Richard F. Schlenk, Marlies Götz, et al.. (2013). PRAME-Induced Inhibition of Retinoic Acid Receptor Signaling-Mediated Differentiation—A Possible Target for ATRA Response in AML without t(15;17). Clinical Cancer Research. 19(9). 2562–2571. 31 indexed citations

20.

Schmitt, Michael, Agnieszka Bojarska−Junak, Anna Dmoszyńska, Krzysztof Giannopoulos, & Jacek Roliński. (2009). Expression of HLA-G in patients with B-cell chronic lymphocytic leukemia (B-CLL).. SHILAP Revista de lepidopterología. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact